Najah
ABI-GERGES, PhD
| Najah Abi-Gerges, PhD, is Vice President of Research & Development at AnaBios. Dr. Abi-Gerges holds a MSc in Physiology and Pharmacology from the University of Poitiers (France) and a PhD in Cardiac Physiology from Paris XI University (France). Prior to joining AnaBios, Dr. Abi-Gerges was involved in drug discovery programs at AstraZeneca plc.
With over 17 years in the pharmaceutical industry, he is an innovative leader, having made substantial contributions to drug approvals (like Tagrissoâ, a treatment for metastatic EGFR T790M mutation-positive non-small cell lung cancer), research across several areas of cardiac physiology and pharmacology resulting in over 40 published peer-reviewed articles, and novel paradigms to advance cardiovascular translational science. Dr Abi-Gerges is the Editor for the Journal of Pharmacological and Toxicological Methods, and is also a reviewer for more than 20 peer-reviewed scientific journals and review judge panel for various science institutes and foundations. Dr. Abi-Gerges is co-chair of the ion channel group in the CiPA initiative. |
